two 9p21 region marker snPs previously identified by the CarDIoGraMplusC4D Consortium study, of which arIC was a part. We then tested each marker snP genotype effect on prediction of CHD within sub-groups of the arIC sample defined by traditional CHD risk factors by applying a novel multi-model strategy, PrIM. We observed that the effects of snP genotypes in the 9p21 region were strongest in a subgroup of hypertensives. We subsequently validated the effect of the region in an independent sample from the Copenhagen City Heart study. Our study suggests that marker snPs identified as predictors of CHD risk in large population based GWas may have their greatest utility in explaining risk of disease in particular sub-groups characterized by biological and environmental effects measured by the traditional CHD risk factors.
Introduction
Coronary heart disease (CHD) is a major contributor to global human morbidity and mortality. addressing the human cost of CHD has been a major focus of basic research, implementation of health policies and selection of options for clinical care. High-density genotyping assays have been used in large samples to identify human chromosomal regions harboring relatively common (minor allele relative frequency >0.01) single nucleotide polymorphism (snP) markers of genomic variations that determine the genetic architecture of risk of CHD. Meta-analyses, which combine samples from multiple studies to produce even larger sample sizes, have both confirmed snP marker associations from previous studies and identified novel phenotype-genotype associations. the results of such large-scale studies have identified statistically significant associations between risk of disease and more than two dozen regions across the human genome (IBC 50K CaD Consortium 2011; Zeller et al. 2012) . among these, snPs marking variation in the chromosome 9p21 region have been the strongest and most reproducible GWas CHD hits (odds ratios on the order of 1.2-1.3) (assimes et al. 2008; schunkert et al. 2011; Palomaki et al. 2010; Deloukas et al. 2013; Dong et al. 2013; lee et al. 2013 ) that have been detected in large cohorts representing several different ethnicities.
While these studies estimate the average, or marginal, effects of the marker snPs, they may not be representative of any of the many sub-groups of individuals that make up the population at large. evidence for this is provided by the observation that 9p21 marker snPs have been inconsistent predictors of CHD risk (talmud et al. 2008; Brautbar et al. 2009; Paynter et al. 2009; shiffman et al. 2011; nambi et al. 2012) . as an example, a study by Brautbar et al. (2009) found that snP rs10757274 genotypes improved CHD risk prediction beyond traditional risk factors among white participants of the atherosclerosis risk in Communities (arIC) study, while in the Women's Genome Health study snP genotypes for rs10757274 did not improve prediction (Paynter et al. 2009 ). this suggests that the 9p21 region effects may be most relevant for predicting risk in particular groups of individuals defined by other risk factors or environmental strata (i.e., genotype by environment interaction, or G × e). Previously published studies have reported G × e effects on CHD risk in this region with traits such as diet, alcohol, smoking and waist-to-hip ratio (Ye et al. 2008; Hu et al. 2009; Do et al. 2012) . these results and others serve as documentation that even the strongest GWas signals for common complex diseases like CHD can be influenced by context.
In this study we ask, who might benefit the most from genetic information on the chromosome 9p21 region garnered from large-scale GWas. to address this question we investigate the predictive effects of two 9p21 region marker snPs (rs1333049 and rs3217992) identified by the CarDIoGraMplusC4D consortium, a collaboration involving more than four dozen different CaD cohorts of european and asian descent (Deloukas et al. 2013 ). We first establish whether these two snPs make a statistically significant contribution to explaining risk of CHD in the arIC sample, which was a part of the CarDIoGraM consortium. next, we evaluate the 9p21 region marker snP effects in sub-groups of individuals defined by values of the traditional CHD risk factors that are markers of biological and environmental context. last, we test whether the context dependency of the effect of the 9p21 region, observed in hypertensives from the arIC study, is validated in an independent sample of hypertensives from the Copenhagen City Heart study (CCHs).
Results
a description of the sample of 7,589 european american arIC participants (3,869 females and 3,720 males) considered in this study is presented in table 1. there were 1,177 individuals (15.5 % of total sample) diagnosed with CHD. the relative frequencies for each of the categorized traditional risk factors (trFs), with the exception of community, were significantly different between those with and without CHD (p < 0.001 for all trFs except community: p = 0.327). CHD cases had a larger proportion of males and older (age 55-64) individuals. as expected, CHD cases also tended to have a less favorable health profile (i.e., larger proportion of overweight/obese, low HDl-C, high total cholesterol and triglycerides, stage 1 or 2 hypertension and diabetics) compared to those without CHD.
Both of the chromosome 9p21 region marker snPs that were identified as having genome-wide significant effects by the CarDIoGraMplusC4D study were directly genotyped (i.e. not imputed) in the arIC study (table 2) . In each case the minor allele was the risk-conferring allele, and both were very common. the minor allele relative frequency (MarF) for rs1333049 was 0.478 and the MarF for rs32179921 was 0.378. We detected statistically significant (p < 0.05) CHD-snP associations in the arIC sample for both of these snPs. the odds of CHD adjusted for age and gender was increased by ~17 % for each additional risk allele copy of rs1333049, while the per-allele increase in odds of CHD was 22 % for rs3217992. these effect estimates were consistent with those observed in the CarDIoGraMplusC4D meta-analysis (Or = 1.23 for rs1333049 and Or = 1.16 for rs3217992, see table 2).
We next applied the modified patient rule induction method (PrIM) to define the CHD risk spectrum for the arIC sample using the set of traditional CHD risk factors.
the PrIM is an iterative process that partitions the sample according to values (or combinations of values) of the risk factors (for more details, please see " Methods" and Friedman and Fisher 1999; Dyson et al. 2007 Dyson et al. , 2009 . Using the values of the trFs, seven unique, sequential sub-groups and a remainder subgroup were defined by the PrIM analysis of the arIC sample (Fig. 1) . the relative frequency of CHD (θ) ranged from 0.03 to 0.39 across the sub-groups and remainder (Fig. 1) . these sub-groups can be divided into three broader risk categories of partitions. the first and second partitions comprise the high-risk category. relative frequencies of CHD are 0.39 (95 % CI = 0.36, 0.42) in P 1 and 0.26 (95 % CI = 0.23, 0.29) in P 2 , both significantly higher than that of the total arIC sample (θ = 0.16, see Fig. 1 ). these high-risk sub-groups capture over half of all CHD cases in the total sample (652/1,177 = 55.4 %). Partitions 3, 4 and 6 are sub-groups at moderate risk, with relative CHD frequencies approximately equal to the overall relative frequency in arIC (θ = 0.16-0.17 for P 3 , P 4 and P 6 ). lastly, sub-groups 5, 7 and the remainder are low-risk subgroups, with relative frequencies of CHD significantly lower than that of the total arIC sample (θ = 0.11, 0.09 and 0.03 for P 5 , P 7 and remainder, respectively).
the first partition (P 1 ) consisted of males with stage 2 hypertension (N = 930). after removing the 930 males included in P 1 , the PrIM defined a second partition (P 2 , 1 3 N = 1,097) that includes two sub-groups: (1) 653 older (age ≥55) females or males with low HDl-C and elevated total cholesterol and 2) 444 diabetic females or males. the third partition (P 3 , θ = 0.17, 95 % CI = 0.15, 0.20) included 594 males with elevated triglycerides (≥150 mg/dl) who did not have stage 2 hypertension or diabetes. the fourth partition (P 4 , θ = 0.16, 95 % CI = 0.14, 0.20) included 727 males with elevated total cholesterol (≥200 mg/dl)), low triglyceride concentration (<150 mg/dl), no stage 2 hypertension and no diabetes. the fifth partition (P 5 , θ = 0.11, 95 % CI = 0.10, 0.13) was defined by 955 females with either stage 1 or stage 2 hypertension who were non-diabetic and 55 males with stage 1 hypertension who had low total cholesterol and triglyceride levels and were non-diabetic. after excluding members of P 5 , the relative frequency of CHD cases in the sixth partition was 0.16 (95 % CI = 0.11, 0.20). this partition was composed exclusively of older males (aged 55 and over) who had low total cholesterol, low triglyceride levels, no hypertension and no diabetes. PrIM defined a seventh partition of 623 female current smokers who were both normotensive and non-diabetic and 128 male current smokers who were younger (<55 years old) with low total cholesterol, low triglyceride levels, no hypertension and no diabetes. the relative frequency of CHD in P 7 was 0.087 (95 % CI = 0.07, 0.11), an almost 44 % reduction from that observed in the total sample Fig. 1 PrIM analysis of CHD risk in arIC european american sample using traditional CHD risk factors (θ = 0.16). after excluding the members of P 7 , the relative frequency of CHD in the remainder sub-group of 2,117 individuals was 0.03 (95 % CI = 0.03, 0.04), which was a ~79 % decrease in the relative frequency of CHD cases compared to the total sample. the remainder consisted of 1,753 females and 364 males who were non-smokers, normotensive and non-diabetic. the 364 males were also younger than 55 years and had both low total cholesterol and low triglyceride levels. We next tested the significance of the CHD risk predictive effects of each of the chromosome 9p21 region marker snPs in each of the sub-groups defined by the PrIM analysis of the trFs (Fig. 1) . We observed that the relative frequency of CHD did not vary significantly among subgroups 3, 4 and 6, (θ = 0.17 for P 3 , θ = 0.16 for P 4 and θ = 0.16 for P 6 ). We therefore combined these sub-groups into one risk sub-group for the CHD-snP association tests carried out here.
CHD risk was not significantly associated with either rs1333049 or rs3217992 in the two lowest risk sub-groups: PrIM partition 7 and the remainder (table 3) . there was evidence of significant context-dependent effects for both snPs in the highest risk PrIM partition, P 1 , composed of stage 2 hypertensive males. the odds ratio was 1.24 for rs1333049 (95 % CI = 1.03, 1.49) and 1.36 for rs3217992 (95 % CI = 1.11, 1.66). there was also a context-dependent association in the sub-group of individuals with stage 1 or stage 2 hypertension (partition P 5 ) for both 9p21 snPs. the odds ratio for CHD was 1.37 for rs1333049 (95 % CI = 1.04, 1.80) and 1.43 for rs3217992 (95 % CI = 1.07, 1.91). We note that only females with stage 2 hypertension were included in P 5 because males with stage 2 hypertension were included in P 1 . additionally, the odds of CHD associated with snP rs3217992 (but not rs1333049) was significantly increased in the second highest risk group, P 2 , defined by individuals with either low HDl-C, high tC and older age or diabetes (Or = 1.25, 95 % CI = 1.02, 1.52, see table 3).
We next evaluated whether the context dependency observed among PrIM partitions of the arIC participants was consistent with a difference in the 9p21 CHD risk effects according to hypertensive status. Both snPs had statistically significant effects on CHD risk in sub-groups 1 and 5. Partition 1 encompassed all 930 males with stage 2 hypertension, while partition 2 was composed of all females (N = 950, stage 1 or stage 2) and males (N = 57, stage 1 only) with hypertension that were not included in sub-groups 2-4. In table 4, we dichotomize the arIC sample by hypertensive status (stage 1 or 2 vs. normotensive) and test the CHD risk effects for snPs rs1333049 and rs3217992 separately in these two groups. We find that variation in CHD risk is significantly associated with variation at snP rs1333049 in hypertensives (p = 0.017) but not normotensives (p = 0.091), and the CHD risk effect of snP rs3217992 is statistically significant in both the hypertensive and normotensive groups (p < 0.001 and p = 0.044, respectively). However, we note that the increase in risk of CHD associated with rs3217992 in the sub-group of hypertensives is double that observed in the normotensive sub-group. specifically, the odds of CHD for each additional risk allele increases by 29 % (Or = 1.29, 95 % CI = 1.13, 1.48) among hypertensives and 14 % (Or = 1.14, 95 % CI = 1.00, 1.30) among normotensives. Table 3 association test results for chromosome 9p21region snP markers among PrIM sub-groups of the arIC sample Bold indicates statistical significance at α = 0.05 a PrIM sub-groups were defined as follows: P 1 = Males w/stage 2 hypertension; P 2 = Older (age ≥55) individuals w/low HDl-C (<45 mg/dl) and elevated total cholesterol (≥200 mg/dl) or diabetics; P 3 = Males w/elevated triglycerides (≥150 mg/dl); P 4 = Males w/elevated total cholesterol; P 5 = Individuals with stage 1 or stage 2 hypertension; P 6 = Older males; P 7 = Current smokers b Ors, 95 % CIs and p values from an unadjusted additive genetic model; genotypes coded as having 0, 1 or 2 copies of risk allele c sub-groups 3, 4 and 6 were combined for snP-CHD association tests because the relative frequency of CHD was not significantly different among these sub-groups snP PrIMsub-groups a P 1 P 2 P 3 , P 4 and P 6 c P 5 P 7 remainder Overall to further explore this context dependency, we evaluated the effects of the 9p21 region in an independent sample of CCHs participants, dichotomizing the CCHs into risk sub-groups based on hypertensive status (defined in CCHs as ever vs. never hypertensive). two snPs marking the 9p21 region were genotyped in CCHs: rs10757274 and rs2383206. IHD risk was significantly associated with both of these snPs in the total CCHs sample (table 5) . We found the odds of IHD were significantly associated with snP rs10757274 genotypes in the ever hypertensive sub-group, while there was no significant IHD-genotype association in the never hypertensive sub-group (table 5, Or = 1.12, 95 % CI = 1.02, 1.22 for ever hypertensive group, Or = 1.07, 95 % CI = 0.90, 1.27 for never hypertensive). there was also suggestive evidence (p = 0.06) of a IHD-genotype association among ever hypertensives for snP rs2383206, with the direction of effect consistent with that observed for 9p21 marker snPs in arIC and rs10757274 in CCHs (Or = 1.09, 95 % CI = 1.00, 1.19). We did not find a significant IHD-genotype association for rs2383206 in the never-hypertensive group (Or = 1.06, 95 % = 0.90, 1.26).
Discussion
the ubiquity of context dependency in the natural world is a biological reality It should be widely acknowledged that neither genes nor environments, but their interactions, are the primary biological causes of phenotypic variation (lewontin 2002; sing et al. 2003; noble 2006, 2008; lehner 2011) . the primary insights gained from decades of biological research establish that interactions between molecular components of every biological system are pervasive at every level explored to date. theoretical and experimental studies ranging from single cell organism control of gene expression; to metabolic, ontogenic and pathophysiological pathways in multicellular organisms; to homeostatic regulatory mechanisms; to ecosystem dynamics; to coevolutionary relationships and processes; all point to the overriding framework of context-dependent effects and the multiple interactions that comprise them (templeton 2006) . even in disease states where genetic architecture is often well characterized and considered to be classically Mendelian with respect to causation (e.g. cystic fibrosis, sickle cell anemia, etc.), genetic and environmental context-dependent effects are well known (neel and schull 1954; scriver et al. 2000; rimoin et al. 2006) . Coarse-and fine-grained structural, functional, temporal, and spatial heterogeneities are now well documented in the studies of complex traits in many organisms (templeton 2006). Indeed, "where complex genetic traits loom, epistasis is not far behind" (Frankel and schork 1996) . It is now axiomatic for complex traits in model organisms that contexts defined in terms of gene-gene and gene-environment interactions are major contributors to producing phenotypes, a fact that is also fundamental to the principles of evolutionary genetics (templeton 2006) . there is no compelling reason why humans should be any different (Mackay 2001). the same can be said with confidence about the interaction of genomic effects with the effects of the environment, both internal and external to the organism. the overall function of the genome involves interactions among many structural components (protein coding sequences, regulatory sequences including non-coding rnas, and epigenetic marks) whose functions are influenced by the environmental context defined by the cell. Furthermore, it has become widely appreciated that these separate components and their interactions do not influence phenotypes independent of variations in the micro-cellular or macro-organismal environments (Jirtle et al. 2007; Weiss and Buchanan 2009) . as noble (2006, 2008) and lewontin (2002) have so clearly summarized, the Dna sequence is only part of the material basis of heredity. the biological functions associated with a contiguous region of Dna sequence are determined by the interactions of its effect with the effects of environmental agents, including other regions of Dna sequence, that occur throughout the life cycle from fertilization until death. (Holdt and teupser 2012) . Considerable attention has also been devoted to exploring the role of gene-environment interactions involving 9p21 region variants on CHD risk. Do et al. (2012) detected a significant interaction between rs2383206 and dietary measures ("prudent diet" score) contributing to MI risk in the InterHeart study, composed of european, south asian, Chinese, latin american and arab individuals. to confirm this result they tested for gene-diet interaction in the FInrIsK cohort, and also found a significant interaction effect between rs4977574 and diet (quantified by fruit, vegetable and berry consumption) on CvD risk. a study in an Italian sample identified a significant interaction between a measure of obesity (waist-to-hip ratio) and rs1333049 genotypes on CvD risk. Hu et al. (2009) found that the relationship between hypertension and ischemic stroke risk differed according to rs2383206 genotype (aG/GG vs. aa) in a sample of Han Chinese, although interaction was evaluated in a logistic regression model and not defined in a context-dependent manner as we do here in our PrIM analysis. significant interactions of rs2383206 genotypes with smoking and alcohol consumption were also reported in Hu et al. (2009) . However, other studies have failed to find significant evidence of G × e. Of particular interest, Folsom et al. (2012) analyze Caucasians from the arIC cohort for interactions between rs10757274 and a litany of risk factors and biomarkers, including hypertension, and find no significant evidence of interaction effects on incident CHD. regardless of the result, these findings complement our work by exploring the role of context on CHD risk attributed to variation in this genomic region and providing further evidence that the effects of 9p21 region are dependent on particular biological-environmental contexts. so why is there so little evidence for G × G and G × e effects from genetic studies of CHD?
GWas, meta-analyses and linear regression models fail to accommodate biological reality estimating genetic architecture using GWas assumes additive snP marker effects and no interactions with environments. large-scale GWa studies combining data from multiple study populations are based on the premise that larger sample sizes lead to increased power to detect common variants with relatively modest effects that act independently in determining disease risk. such studies have found highly significant associations between risk of CHD and dozens of snPs. the meta-analysis on which this paper is based reported 48 significant CHD-snP associations, 20 of which were previously reported in CarDIoGraM and 28 which were either different marker snPs for previously reported gene regions or novel findings (Deloukas et al. 2013 ). However, as more heterogeneity is introduced in a study, pooling data can result in decreased power to detect effects; in other cases, collapsing over (unobserved) genetic and environmental contexts can generate false positive results irrespective of type I error rate adjustment. the results of our study are consistent with the hypothesis that genetic contributions to CHD include many instances of context-dependent genotypic effects that will (1) not be detected in large phenotypically heterogeneous samples where CHD-appropriate precise contexts are disregarded or (2) be attributed to modest population-level genetic effects when much larger and clinically relevant effects are present in a particular environmental context. the statistical methods used to detect interactions in previous studies of the influences of G × e interaction on risk of CHD reviewed above are based on the application of traditional linear regression models. these models assume that statistical interaction between two variables (e.g., G × e) is a deviation of the combined snP-environment effects from the marginal effects of each of the variables; statistically, it is an analysis of the residual effects after accounting for the additive marginal effects of the variables. since the analysis of interaction is dependent on the strength of the marginal effects, it is also dependent on the definition and form of the marginal effects in the model framework (Wang et al. 2010) . this is important to note because in observational studies with unbalanced data, genotypic and environmental effects are correlated with their relative frequencies, which confounds estimation of marginal effects and interaction effects. Further, widespread evidence that different combinations of genetic and environmental factors are responsible for the phenotype of a trait having a complex etiology in different sub-groups of individuals in the population at large suggests that this assumption is false (Cowper-sal Iari et al. 2011) .
the PrIM redefines G × e as dependency of genetic effects on environmental context
In this study we use the PrIM to present an alternative definition of interaction; here we define G × e interaction as the failure of the multi-variant genotype effects defined by a genomic region to be homogeneous across strata defined by measures of the environment. Our approach allows us to avoid the usual assumptions about marginal genotypic/ environmental effects by establishing unique sub-groups of individuals based on combinations of traditional CHD risk factors and snP genotypes and then testing homogeneity of the relative frequency of CHD across subsamples.
Biological-physiological-phenotypic characteristics of the 9p21 region and hypertension the snP markers evaluated here are located in (rs3217992) or downstream (rs1333049, rs10757274, rs2383206) of the protein-coding CDKN2A/2B genes. the CDKN2A/2B genes code several different proteins that are involved in cell proliferation and apoptosis, including regulating the tumor suppressor p53 protein (Dominguez-Brauer et al. 2010; Holdt and teupser 2012) . these regulatory activities are essential to vasculature remodeling and development of atherosclerosis (lusis 2000). Further evidence from gene expression studies suggests variation in this region impacts expression of both CDKN2B and ANRIL isoforms (Cunnington et al. 2010; Holdt et al. 2010; Johnson et al. 2013) . ANRIL is a long CDKN2B antisense noncoding rna, and while the functional relevance of ANRIL has not been entirely resolved, it is hypothesized to regulate genes involved in cellular proliferation, a process also important in atherosclerosis (roberts and stewart 2012). a recent functional analysis of vascular smooth muscle cells (vsMCs) found that variation in 9p21 marker rs1333049 was associated with variation in CDKN2A/2B-encoded cell proliferation regulator and ANRIL expression levels, as well as vsMC proliferation itself, in both normal and atherosclerotic tissue samples (Motterle et al. 2012 ). a pair of recent studies has also explored the potential of variants in this region to affect nearby transcriptional regulatory elements, but produced inconsistent results (Harismendy et al. 2011; almontashiri et al. 2013; Musunuru et al. 2013) . although the exact mechanism of action is not yet resolved, the consensus remains that this region is involved in the development of atherosclerosis.
this functional evidence supports our finding that the CHD risk effects of variants in this region are concentrated among individuals with hypertension. there is a long history dating back almost 50 years documenting the relationship between hypertension and atherosclerotic plaque formation (Freis 1969; Hollander 1976; simon et al. 1997) . elevated blood pressure is believed to contribute to plaque formation and subsequent tearing by inducing stress on endothelial cells which triggers an inflammatory response (Chobanian 1992; schiffrin 1998) . the impact of hypertension on atherosclerosis is particularly strong among those with other risk factors such as dyslipidemia (Kannel 1990) . thus, it is plausible that the combination of 9p21 marker variants and hypertension has a stronger effect on CHD risk than the 9p21 marker variants in a normotensive background, whether the risk-raising effects are mediated via atherosclerotic processes or otherwise.
validation (not replication) of 9p21 region context-dependent effects in an independent sample
We were able to validate the context-dependent association in the 9p21 region observed in arIC using two additional marker snPs (rs1075274 and rs2383206) genotyped in an independent sample of Danish participants of the CCHs. We emphasize that we are not strictly "replicating" the arIC results because we have not tested those results in the same population of inference. We have simply found that the impact of variants marking this region on CHD risk appears to be stronger among hypertensive individuals than those without hypertension in two distinct study populations. the contexts themselves are not identical in arIC and CCHs participants because the underlying distributions of traditional CHD risk factors are heterogeneous between the two cohorts. Further, we note that definitions of both the endpoint (CHD/IHD) and hypertension were different in each of the cohorts. logically, we would not expect to define identical risk sub-groups in both samples, given the different study designs, risk factor definitions, and phenotypic and allelic heterogeneity between the two populations of inference. In fact, one might argue that the arIC and CCHs results constitute two distinct contextdependent effects, both equally valid in their respective populations of inference. Perhaps the consistent findings in spite of this heterogeneity make an even stronger case for a hypertensive-dependent effect of 9p21 region variants on CHD risk. although the context-dependent effects in CCHs are not as strong as those observed in arIC, our study suggests that the marginal 9p21 marker effects are concentrated among individuals who either have or have a history of hypertension.
Conclusion
We present a statistical approach consistent with the goal of personalized medicine to identify which genetic variants, in which environmental and genetic contexts, in which sub-groups of individuals best predict risk of disease. Phenotype-genotype studies that ignore context will find marginal snP effects that, on average, are statistically significant, but whose clinical utility is restricted to a specific group of individuals. By defining multiple populations of inference, we are able to demonstrate that marginally significant snPs identified in the total sample are actually attributable to strong context-dependent genotypic effects in particular sub-groups of the sample. these results imply that both gene-environment and gene-gene interaction are essential to defining the genetic architecture of common complex diseases such as CHD.
Methods

study populations
the arIC study is an ongoing prospective cohort study begun in 1987 that is designed to investigate the risk factors for atherosclerosis and its clinical sequelae in samples of european americans and african americans from each of four United states communities: Forsyth County, north Carolina; Jackson, Mississippi (african americans only); northwestern suburbs of Minneapolis, Minnesota; and Washington County, Maryland. a baseline survey was conducted on females and males aged 45-64 years between 1987 and 1989 (the arIC Investigators 1989 . the sample we studied included 7,589 european american participants (3,869 females, 3,720 males) with complete trait data from the baseline survey and genotype data from the affymetrix 6.0 genome-wide snP array. Institutional review boards at all participating institutions approved the procedures used in collecting and processing of participant information. Informed consent was obtained from all participants.
For confirmatory analyses we used data from the CCHs, a large, prospective study representing the adult (20 years and older) Danish population. Participants were randomly selected from the national Danish Civil registration system and initially examined in 1976 -1978 , with follow-up exams occurring in 1981 -1983 , 1991 -1994 and 2001 -2003 (Frikke-schmidt et al. 2004 , 2008 Haase et al. 2010) . Our analyses included 9,073 participants (5,151 females, 3,922 males) with complete trait information and available Dna samples from the third exam (1991) (1992) (1993) (1994) (schnohr et al. 2001 ). all participants gave informed consent, and the study was approved by the Danish ethics Committee for the City of Copenhagen and Frederiksberg (no. 100.2039/91) .
trait definitions
For the arIC sample, methods for measuring the traits considered here [body mass index (BMI), plasma lipids and lipoproteins, blood pressure, smoking, coronary heart disease] have been published elsewhere (53). Briefly, age was measured in years. Body mass index (BMI) was computed as weight (in kilograms) divided by height (in meters) squared (i.e. kg/m 2 ). total cholesterol (siedel et al. 1983) , high-density lipoprotein cholesterol (HDl-C; Warnick et al. 1982) and triglycerides (nägele et al. 1984) were measured using standardized clinical laboratory methods as cited and concentrations reported in milligrams per deciliter (mg/dl). We excluded participants that were taking lipid lowering medications. Blood pressure measurements were reported in mmHg. an individual was classified as diabetic if they met one or more of the following criteria: (1) a fasting glucose level >126 mg/dl, (2) a non-fasting glucose level >200 mg/dl, (3) use of diabetic medications or (4) a self-reported physician diagnosis of diabetes (american Diabetes association 2004). smoking was identified by self-reported current smoking status. Incident coronary heart disease (CHD) status was defined as any combination of definite or probable myocardial infarction (with hospitalization), fatal coronary heart disease, cardiac procedure or MI defined by electrocardiogram (eCG) serial changes as of December 31, 2004 (Machado et al. 2006 . We also included prevalent CHD cases at baseline, which were defined as a self-reported history of MI (physician-diagnosed or hospitalization), cardiac procedure or MI defined by eCG. Diabetes, current smoking and CHD phenotypes were dichotomized as "yes" or "no" depending upon criteria defined above.
For statistical analyses, each trait was categorized as follows: age was categorized in two groups: (1) 45-54 years and (2) 55-65 years. BMI was categorized into three groups: (1) <25 kg/m 2 (normal), (2) 25 kg/ m 2 ≤ BMI ≤ 29 kg/m 2 (overweight) and (3) BMI ≥30 kg/ m 2 (obese). Plasma lipid categories were based upon the nCeP atP III guidelines (national Cholesterol education Program 2002) and plasma lipoprotein categories were based upon inferences from Framingham Heart study (Gordon et al. 1977) . total cholesterol was categorized into three groups: (1) <200 mg/dl, (2) 200-239 mg/dl and (3) ≥240 mg/dl. HDl-C was categorized into three groups: (1) <45 mg/dl, (2) 45-59 mg/dl and (3) ≥60 mg/dl. triglyceride was categorized into two groups: (1) <150 mg/dl and (2) ≥150 mg/dl, Blood pressure phenotype was categorized into three groups: (1) stage 2 hypertension (diastolic blood pressure ≥100 mmHg and/or systolic blood pressure ≥160 mmHg and/or taking hypertensive medication), (2) stage 1 (borderline) hypertension (diastolic blood pressure 90-99 mmHg and/or systolic blood pressure 140-159 mmHg) and (3) "normal" blood pressure (diastolic blood pressure <90 mmHg and systolic blood pressure <140 mmHg). the stage 1 and stage 2 hypertension categories are consistent with JnC 7 guidelines (Jones and Hall 2004) .
For the CCHs sample, an individual was considered "ever hypertensive" if they satisfied at least one of the following criteria: (1) systolic blood pressure ≥140 mg/dl, (2) diastolic blood pressure ≥90 mg/dl or (3) taking antihypertensive medication at one or more exams. Ischemic heart disease (IHD) was diagnosed based on WHO International Classification of Diseases, 8th edition, codes 410-414, and 10th edition, codes I20-I25 (stengård et al. 2007 ). all individuals included here were free from IHD at baseline; incident IHD was evaluated from baseline to December 31, 2010. Individuals who at none of the BP measurement times had a systolic BP >140 or a diastolic BP >90 fell into a group called "never hypertensive." snP selection
We considered two snPs marking the chromosome 9p21 gene region, rs1333049 and rs3217992, which were reported in the CarDIoGraMplusC4D Consortium study (Deloukas et al. 2013 ). CarDIoGraMplusC4D included 67,376 CaD cases and 142,664 controls in a two-stage meta-analysis with a third stage for validation. For the meta-analysis, rs1333049 was chosen as the lead snP based on previously published GWas findings, while rs3217992 was identified as an additional signal in the 9p21 region "independent" of the lead snP (r 2 = 0.5). Both of these snPs were genotyped in our arIC sample using the affymetrix 6.0 snP array. relative genotype frequencies for each of the two snPs did not deviate significantly from Hardy-Weinberg equilibrium at α = 0.05. For analyses in the sample from the CCHs, snPs rs10757274 and rs2383206 were available as markers of the 9p21 locus. available HapMap CeU sample estimates indicate that rs2383206 is in strong lD (r 2 > 0.8) with rs1333049 but not with rs3217992 (Barrett et al. 2005) . three of the four snPs (rs10757274, rs2383206 and rs1333049) are within 30 kb of each other and the fourth (rs3217992) is 100 kb upstream from the others.
statistical methods
For each snP, we used logistic regression and the arIC data to estimate the odds of CHD associated with the risk allele defined by the CarDIoGraMplusC4D study (Deloukas et al. 2013) . In this way, individual snP genotypes were coded as 0, 1 or 2 based on the number of copies of the risk allele. We adjusted each snP-CHD association for age and gender. We used a nominal α level of 0.05 to evaluate statistical significance.
PRIM (patient rule induction method)
For this study we ask whether the marginal 9p21 region marker snP effects are homogeneous among sub-groups of individuals identified by PrIM using the traditional risk factors. Dyson et al. (2007 Dyson et al. ( , 2009 ) have modified the PrIM algorithm, originally proposed by Friedman and Fisher (1999) , to address this question. Here, our application of the PrIM treats all cases of CHD as equivalent in a crosssectional analysis that does not consider time to event. the PrIM sequentially partitions a sample into mutually exclusive sub-groups through an iterative peeling and pasting process. Peeling creates a partition by excluding sub-groups of individuals based on specific values of (one or more) predictor variables, while pasting subsequently amends individuals from the remainder to the partition based on values of predictor variables. sub-groups are defined to maximize θ, the relative frequency of individuals with CHD, given the partition satisfies the support parameter, β. β is the minimum proportion of individuals, among those who are not already assigned to a partition, required to create a new partition. We use a likelihood-based grid search to choose the optimum β for each PrIM application across a range of values from 0.05 to 0.50 (in increments of 0.005) (Dyson et al. 2007) . Only sub-groups with a statistically significant θ, tested against a theoretical null distribution derived by Dyson and sing (in press) , are retained in the peeling and pasting process. Individuals not assigned to a partition after peeling and pasting is completed make up a remainder subsample which is then used to carry out a second peeling and pasting cycle to create a second partition and a remainder subsample. this algorithm continues to create partitions until the remainder sample does not produce a sub-group that satisfies the statistical significance of θ. to adjust for the multiple hypothesis tests associated with the peeling and pasting to establish the completed set of sub-groups, we used a nominal α level of 0.023, corresponding to an experiment-wise threshold of α = 0.05 (details given in Dyson et al. 2009 ).
